Podcasts about Leukemia

In this conversation, Jeff interviews MK Holmes, the campaign development manager for the Light the Night campaign with the Leukemia & Lymphoma Society (LLS). They discuss MK's background, her journey to LLS, and the impactful work the organization does in the community, particularly through events like Light the Night and the Pickleball for a Purpose tournament. MK shares insights into LLS's mission to cure blood cancers, the support they provide to patients, and how the community can get involved through fundraising and volunteering.Leukemia and Lymphoma SocietyCLICK HERE to donate to Jamie's Light the Night FundraiserCLICK HERE to register for Charlotte Light The Night 2025Special thanks to:The Carolina Factory & The Vannelle Family---------------------------------------------------------------------------------------The Best of LKNhttps://thebestoflkn.com/Hosted by:Jeff HammReal Estate BrokerCharlotte & Lake Norman (NC)https://lknreal.com/Support the show

In this episode of the Epigenetics Podcast, we talked with Ani Deshpande from Sanford Burnham Prebys about his work on epigenetic regulation and developing small molecules through high throughput screens for AML. Throughout our discussion, we delve into Dr. Despande's journey into the field of biology and science, tracing his evolution from a literature enthusiast in Mumbai to a dedicated cancer researcher. He reflects on his formative experiences during his PhD at Ludwig Maximilian University in Munich, where she developed murine models for refractory acute myeloid leukemia (AML). We examine these models' contributions to therapeutic discovery and understanding the intricate mechanisms underscoring AML's complexities. Transitioning to his postdoctoral work at Scott Armstrong's lab in Boston, Dr. Despande shares his insights on the importance of epigenetic regulators, such as DOT1L, in leukemias, and how they can serve as strategic therapeutic targets. His ambitious pursuit of translational research is further highlighted through his efforts in developing a conditional knockout mouse model and his collaborative work utilizing CRISPR technology to refine our understanding of epigenetic regulation in cancer pathogenesis. Moreover, we engage in a conversation about the challenges and opportunities that arise when establishing his lab at Sanford Burnham Prebys. Dr. Despande candidly discusses the delicate balance between pursuing topics of genuine interest versus adhering to grant fundability, underlining the tension researchers face in the current scientific landscape. His emphasis on the critical need for innovation within lab settings serves as a motivational call for emerging scientists to venture beyond the established templates that often inhibit groundbreaking discoveries. We conclude our dialogue with an exploration of his recent projects, which involve targeting specific epigenetic modifiers and how his lab's findings can contribute to greater understanding and potential treatments for not only AML but also other pediatric cancers driven by gene fusions. Dr. Despande's insights into the integration of modern technologies, such as CRISPR libraries, exemplify his commitment to pushing the boundaries of cancer research. In addition to discussing his scientific contributions, we touch upon Dr. Despande's foray into podcasting (The Discovery Dialogues), shedding light on his motivation to bridge the communication gap between scientists and the broader public. He articulates his desire to demystify scientific discoveries and promote awareness about the intricate journey of research that lays the groundwork for medical advancements. This multidimensional discussion not only highlights his scientific achievements but also emphasizes the importance of effective science communication in fostering public understanding and appreciation of research.   References Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006 Nov;10(5):363-74. doi: 10.1016/j.ccr.2006.08.023. PMID: 17097559. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 8;26(6):896-908. doi: 10.1016/j.ccell.2014.10.009. Epub 2014 Nov 20. PMID: 25464900; PMCID: PMC4291116. Sinha S, Barbosa K, Cheng K, Leiserson MDM, Jain P, Deshpande A, Wilson DM 3rd, Ryan BM, Luo J, Ronai ZA, Lee JS, Deshpande AJ, Ruppin E. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nat Commun. 2021 Nov 11;12(1):6512. doi: 10.1038/s41467-021-26788-6. Erratum in: Nat Commun. 2022 May 16;13(1):2828. doi: 10.1038/s41467-022-30475-5. PMID: 34764240; PMCID: PMC8586238.   Related Episodes Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard) The Menin-MLL Complex and Small Molecule Inhibitors (Yadira Soto-Feliciano) MLL Proteins in Mixed-Lineage Leukemia (Yali Dou)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.Find the full published review series in Volume 145 Issue 20 of Blood Journal.

A funeral homily for Mr. Peter Rebello at the church of St. Clement in Toronto on May 20, 2025. Peter died from Leukemia on May 13, the feast of our Lady of Fatima. He was 77.Music: Be not afraid by Bob Dufford with choir.org

Angela started her career as a critical care nurse in 2014. She received her first MSN in 2017 with an emphasis in public health. In 2022, she received her 2nd MSN in Adult/Gerontology Acute Care Nurse Practitioner. She and her husband have been practicing the Keto Diet since 2019 (which was right before COVID and one of their children being diagnosed with Leukemia); with all the stressors that they faced, the Keto Diet kept them healthy and happy through the worst. Disenchanted by modern medicine after learning about the keto diet and reluctant to make the transition as an NP, Angela found her way into Home Health as a Telehealth Primary and Palliative Care NP. Timestamps: 00:00 Trailer 01:25 Introduction 03:15 Nurse practitioner's independence benefits 09:14 ICU nutrition oversights during Covid 11:58 Keto diet and health struggles 14:19 Diet scams vs. genuine support 19:10 Orthopedic surgeon embraces metabolic health 22:33 Low carb lifestyle and nutrition 27:41 Rapid monitoring of hypertension patients 29:42 Revero's unique healthcare model 32:28 Balancing work and family time 34:58 Nutrition and nursing home residents 38:48 Improving elder care nutrition 42:18 Patients' surprising knowledge on keto/carnivore 45:10 Patient struggles in gaining weight 51:13 Creating a positive impact for patients 52:05 Where to find Skye Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Joao wants to know what happens when stem cells of our own, which have been cultivated outside the body, are reintroduced to the bloodstream. This got James Tytko thinking about autologous stem cell transplants, used as a treatment for some forms of blood cancer. He asked Tania Dexter, haematology registrar, and senior medical officer at the Anthony Nolan Institute, to help explain... Like this podcast? Please help us by supporting the Naked Scientists

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RBC antigens. Find the full published review series in Volume 145 Issue 20 of Blood Journal.

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

In this heartfelt episode of the Surviving Siblings Podcast, host Maya Roffler welcomes Cryssy, a bereaved sibling who lost her younger sister, Danielle, to acute myeloid leukemia in 2012. As the oldest sibling, Cryssy took on the role of protector, caregiver, and advocate—navigating the heartbreak of watching her sister battle a devastating illness. Cryssy shares her deeply personal journey of anticipatory grief, the pain of losing Danielle at just 21 years old, and the complex emotions of grieving while trying to stay strong for her family. She opens up about the regret of not getting to say goodbye the way she wanted, the physical toll grief took on her body, and the creative, meaningful ways she keeps Danielle's memory alive every day. This episode is a powerful conversation about sibling loss, anticipatory grief, and finding purpose after tragedy. Cryssy also shares how honoring her sister through traditions, a beloved stuffed animal, and small daily acts has helped her heal—and how grief can manifest physically in ways we might never expect. If you've ever felt the weight of grieving a sibling while being the “strong one” for others, Cryssy's story will remind you that love endures, even through the pain. In This Episode: (00:01:00) – Danielle: A Birthday Gift Sister Cryssy shares how Danielle was born just two days before her own birthday, how they celebrated together, and how their sibling bond was filled with love, chaos, and laughter. (00:04:00) – Big Sister, Protector, Mama Bear Growing up as the oldest, Cryssy stepped into a protective role, helping raise Danielle and their brother, shielding them, and taking on family responsibilities from a young age. (00:05:00) – The Call That Changed Everything Cryssy recounts the moment she learned Danielle was being rushed to the hospital after a bloody nose turned into a leukemia diagnosis—and how she instantly began grieving. (00:08:00) – Facing Acute Myeloid Leukemia Cryssy explains Danielle's diagnosis, the aggressive treatment process, and how she tried to stay hopeful on the outside while preparing herself internally for the worst. (00:11:00) – Holidays in the Hospital Danielle asked Cryssy to decorate her hospital room for Halloween and Christmas—keeping their family traditions alive despite spending their favorite holidays in a hospital room. (00:14:00) – The Final Christmas Together Cryssy reflects on their last Christmas, staying up all night talking, exchanging meaningful gifts, and creating treasured memories in what would be Danielle's final holiday. (00:19:00) – Saying Goodbye Without Words Cryssy shares the experience of Danielle's “surge” before passing, the bittersweet final days, and the deep regret of not being able to say goodbye the way she had hoped. (00:24:00) – Preparing Danielle's Goodbye Honoring her sister's love of style, Cryssy lovingly prepared Danielle for her viewing—painting her nails, doing her hair, dressing her in jewelry, and ensuring she looked radiant. (00:31:00) – A Dream Visit From Danielle Months after Danielle's passing, Cryssy had a vivid dream of Danielle smiling and telling her, “It's okay to be okay”—a powerful, healing moment that brought her comfort. (00:37:00) – Grief's Physical Impact Cryssy opens up about how her grief manifested in physical illness, leading to hospitalization, sepsis, and a near-death experience that she believes Danielle helped her survive. (00:48:00) – Finding Purpose in Grief Cryssy reflects on how grief has shaped her purpose, giving her strength to help others and reminding her that grief is love in a different form. This episode is sponsored by The Surviving Siblings  Connect with Cryssy:  Tik Tok: https://www.tiktok.com/@cryssycryssycryssy Email: Crystalmperry@yahoo.com Instagram: https://www.instagram.com/Nimbeedonut Facebook: https://www.facebook.com/CryssyPerry/ Connect with Maya: Podcast Instagram: https://www.instagram.com/survivingsiblingspodcast/ Maya's Instagram: https://www.instagram.com/mayaroffler/ TikTok: https://www.tiktok.com/@survivingsiblingspodcast Twitter: https://x.com/survivingsibpod Website: thesurvivingsiblings.com Facebook Group: The Surviving Siblings Podcast YouTube: The Surviving Siblings Podcast Patreon: https://www.patreon.com/TheSurvivingSiblingsPodcast  

Imagine the shock and horror of having a child be diagnosed with Acute Myeloid Leukemia, going through treatment for that for 8 months,, relapsing 2 months later, and then being told that the first diagnosis was wrong, and that the child actually had  Ewings Sarcoma. That is what happened to then 2 1/2 year old Connor Mocey who is now 5 years old and doing as well as possible while dealing with this difficult Bone Cancer. 

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

Enjoy a replay of Monday night's Patriots post-draft party co-hosted by Andrew and the Boston Herald's Doug Kyed. Together, they interview ESPN's Mina Kimes, Jason McCourty, Danny Kelly, Danny Heifetz, Phil Perry, Mike Giardi, Taylor Kyles, Michael Hurley, Sam Monson and Steve Palazzolo all about the Patriots draft and potential for next season. Donate at https://princesshallieforever.com — all proceeds go to Doug Kyed's Leukemia and Lymphoma fundraiser in honor of his daughter, Hallie. Pats Interference is presented by: Gametime! Take the guesswork out of buying NFL tickets with Gametime. Download the Gametime app, create an account, and use code CLNS for $20 off your first purchase. Download Gametime today. What time is it? Gametime! Terms apply. Go to ⁠⁠https://gametime.co⁠⁠ ! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffuse large B-cell lymphomas into one of five genetic subtypes. It's an inclusive taxonomy that they say provides actionable genetic information in almost all patients with DLBCL. Finally, new insights on NETS, or neutrophil extracellular traps. In the liver vasculature, NET removal leads to secondary inflammation, resulting in new waves of NETS that may impact future infection. We'll review these and other findings from this recent mouse model study.Featured Articles:Decoding functional hematopoietic progenitor cells in the adult human lungDLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphomaDonor regulatory T-cell therapy to prevent graft-versus-host disease

Visionary of The Year hopeful Nick Schultz is joined by Mike DiGiacomo of the Better Business Bureau at Kooper's North in Mays Chapel on the Maryland Crab Cake Tour to give Nestor the business and fun of fundraising for Leukemia and Lymphoma Society's biggest soiree of the year and the events leading up to the big night in June. The post Visionary hopeful Nick Schultz and Mike DiGiacomo of BBB give Nestor the business of LLS fundraising and big events in May first appeared on Baltimore Positive WNST.

In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

After a short introduction, we replay what Andrew and several media members — Doug Kyed, Mike Giardi, Jeff Howe, Mark Daniels and Michael Hurley — said what the Patriots will and should do with the No. 4 overall pick during last week's live Patriots Draught Party at Vitamin Sea Brewing. Later, the guys offer their favorite mid-round prospects for the Patriots and answer audience questions. Support Doug and the Kyed Family! Donate Here to Help Raise Money for the The Leukemia & Lymphoma Society: https://pages.lls.org/voy/ma/ma25/dougkyed 0:00 Introduction 3:00 Who Should Patriots Take at 4? 6:00 Howe: It Will Be Will Campbell 10:45 Draft Crushes 18:03 Fan Questions 18:05 Will Patriots trade in draft? 19:44 Savage Sports asks question: Campbell or Membou? 27:19 Will Campbell or Mason Graham? 29:30 Fan defends Will Campbell 33:41 Patriots #4 Pick Predictiona Learn more about your ad choices. Visit megaphone.fm/adchoices

Emily McHugh went through a very difficult treatment protocol after being diagnosed with Stage 4 High Risk Neuroblastoma in 2009 before she turned 4 years old. Originally Emily was thought to have had Leukemia. Emily also has had to deal with many side effects from her treatment but still has been able to live as good of a life as possible as she is now a sophomore in college, and will be spending her next academic year at Trinity College in Dublin, Ireland. 

Show Notes: Alison Wakoff Loren went to St Louis to medical school at Washington University. She specialized in internal medicine and later completed a subspecialty fellowship in hematology oncology at the University of Pennsylvania. She met her husband in medical school and they have three children all in their early twenties. Alison  is now the chief of the Division of Hematology Oncology at the University of Pennsylvania, specializing in bone marrow transplantation, a curative therapy for blood cancer. Taking Care of Patients Alison finds the best part of her job to be taking care of patients, especially those who have just been diagnosed with leukemia. She gets to know people when they are in a vulnerable place and understand their lives, which is a privilege. She also does a lot of administrative work, mentoring trainees and faculty, helping them understand their passions and connecting them with opportunities. Alison is proud of her mentoring success stories. She encourages everyone to show gratitude and warmth, as the world is not always generous, and it is important to show that we can make a difference for each other by showing warmth and gratitude. She also shares a story of mentoring a talented MD and PhD candidate who was unhappy in her research role.  Helping Patients with Leukemia Alison discusses the fear and uncertainty people face when discovering they have leukemia. She shares her experiences in delivering sad news to a patient who had been a high school history teacher and had leukemia come back. She mentions that people have incredibly generous spirits and sometimes don't behave their best when they're scared. She also shares examples of people making decisions that matter to their loved ones, such as stopping treatment or continuing treatment when they don't want to. Alison also discusses the range of responses people have when they have to deliver sad news. She explains that most people know they're in for an uphill climb, and it's rare to be surprised. Alison specializes in bone marrow transplants, which are intensive but curative intent therapies, and she emphasizes the importance of laying groundwork ahead of time to make difficult conversations less shocking and offering hope while grounding the conversation. She also stresses the importance of being honest and respectful in her interactions with patients. Fertility Preservation in  Cancer Treatment The conversation turns to Alison's research and the importance of fertility preservation in cancer treatment, which can harm reproductive capacity and lead to infertility. Oncology teams often don't discuss this topic, partly because they are focused on cancer and not reproductive endocrinologists. However, there is a focus on making sure all patients are counseled about the reproductive impact of their treatments and reproductive options to engage in fertility preservation before starting cancer treatments. Alison explains what is recommended for women. She mentions that it is important to discuss these options before starting cancer treatment, as it reduces distress and decision regret for people after treatment. Alison is fortunate to be able to speak and advocate for fertility preservation for people with blood cancers, which represents a special population in oncology care. She has been fortunate to co-chair an effort to develop guidelines for fertility preservation from a large cancer organization. She explains that  colleagues in reproductive science are doing amazing research to extend options for reproductive care before and after cancer treatment, which is exciting to inform oncology clinicians and advocate for insurance coverage for these treatments. Family Life, Running, and Circadian Rhythms Alison shares her experiences with her children, including a daughter who works at the Amherst College Library, an older son considering medical school, and a younger son at Bates College in Maine. Her daughter has inspired her to think about women in the workplace, as she was criticized for not valuing women in her division and for hiring women because they are cheaper. Alison also shares her experience with running, which she enjoys but has to get up early to get in before work. She talks about the concept of morning and night people, stating that people have their own internal clocks. She also mentions that research into the biology of the circadian clock is still in its early stages.  Influential Harvard Courses and Professors Alison shares her experiences at Harvard, including taking courses with Stephen Jay Gould and Dick Lewontin, who were incredibly intelligent and insightful. She also took Act 10 as a senior, which was an unexpected experience that helped her learn different ways of thinking about the subject. Alison  volunteered at the Mission Hill after-school program, which allowed her to get to know the kids and families there. She tried out for various extracurriculars, such as singing and photography, but found it intimidating. She also mentions the training program for photographers. Timestamps: 01:51: Alison Wakoff Loren's Medical Journey  04:12: Motivations and Rewards in Patient Care  22:20: Mentoring Success Stories  22:36: Challenges and Insights in Patient Care  24:17: Balancing Professional and Personal Life  24:32: Research and Advocacy in Fertility Preservation  28:54: Influences and Reflections on Harvard Education  37:25: Extracurricular Activities and Personal Growth  Links: Penn Medicine Website: https://www.pennmedicine.org/providers/profile/alison-loren American Society of Clinical Oncology: https://www.asco.org/ Leukemia and Lymphoma Society: https://www.lls.org/ Featured Non-profit: The featured non-profit of this episode of The 92 Report is recommended by Ming Chen who reports: “ One nonprofit that I've been involved in is the Keswick Foundation, which funds pilot programs in Hong Kong and mainland China to help the community serve needs that are not being met by the government. So we work with family and vulnerable populations. We work with the elderly, and we work with things like helping promote social work in China, as well as clinical psychologists in different NGOs around the region. The other nonprofit that I am on the Advisory Council of is the Asian American foundation, TAF for short, T, A, A, F, F. The Asian American foundation, basically, is a platform that gets together different organizations around anti hate, changing the narrative education, helping to advocate for Asian American history taught in public schools, as well as narrative change representation in Hollywood and beyond. And again, it was founded around the 2020, around the growing disturbing rhetoric against Asians with the rise of COVID So yeah, those are two nonprofit organizations that I'm involved with. So again, one nonprofit that's been on the board for for many, many years is called the Keswick Foundation, and it funds pilot programs in Hong Kong as well as Mainland China. And then the Asian American foundation. If you want to learn more about the Asian American foundation, it's www dot T, A, A, f.org, check it out.” To learn more about their work, visit:  The Asian American Foundation: https://www.taaf.org/ The Keswick Foundation: https://www.keswickfoundation.org.hk/    

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.Featured Articles:Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialDDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysisTargeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat series in volume 145 issue 16 of Blood.

Scientific discovery happens in the lab—but it starts with curiosity and determination. In this episode of Absolute Gene-ius, we welcome Valeria Rangel, a PhD candidate at the University of California Irvine, who shares her research on acute lymphoblastic leukemia and the innovative ways digital PCR is helping uncover genetic patterns linked to cancer in Hispanic populations.Val's work focuses on Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia, a rare and aggressive form of cancer. She explains how her lab uses digital PCR to detect mutations with high precision, identify risk factors in certain populations, and even validate findings using CRISPR-Cas9 gene editing. Through her research, Val sheds light on the role of SNPs, methylation patterns, and translocations in leukemia progression—demonstrating how digital PCR is transforming the way we approach cancer research.Beyond the science, Val takes us on her personal journey, from struggling to break into research due to financial barriers to finding her passion in oncology. In this episode's Career Corner, she shares valuable advice for aspiring scientists, tips for landing research opportunities, and some of her most hilarious and humbling lab moments (yes, she has broken multiple pipettes).Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Special Patreon Re-Release: Love and Loss with James Jetton   James 1:2-4 (NIV) "Consider it pure joy, my brothers and sisters, whenever you face trials of many kinds, because you know that the testing of your faith produces perseverance. Let perseverance finish its work so that you may be mature and complete, not lacking anything."   **Transcription Below**   James Jetton's Bio: My name is James Jetton. I have and still do live a crazy beautiful, challenging, and blessed life. I am blessed to get to raise 4 beautiful children, and I have spent time getting to serve a fantastic community as a Recreation Minister, where I got to combine my love of Jesus, sports, and people. I served in this role for 13 years before my bride Kaetlin was diagnosed with Leukemia in 2020. Unfortunately, after an awe-inspiring journey with cancer, Kaetlin went to meet her Savior in January of 2022.   Clearly, this changed so much of my life trajectory. Currently, I'm working towards obtaining a Masters in Social Work to take the pain and experiences I have had to help others through their pain. Kaet and I were married in 2009 and built a beautiful life; we taught each other so much. So, I deeply desire to take everything we learned together and the lessons the Lord has taught me to help others.   I mentioned earlier that I have 4 exceptional children, Laken, 9, Isla Kaet, 7, Hattie, 6, and Ryder, 4. Laken is my go-getter; she is fearless, strong, and tough. Sweet Isla Kaet is a quiet thinker and planner and is often referred to as little Kaet. She cares deeply and is always looking for ways where she can help and take care of her family. Hattie is our child with special needs and has been diagnosed with GNB-1 Syndrome (a rare genetic disorder). Hattie will light up any room she is in; it's incredible that a child who only has a few words, uses a wheelchair, and is “limited” by our world's standards, can bring joy to people in a way that I never knew was possible. Ryder the caboose is a maniac, and his sisters affectionately call him “Wreck it Ryder” he has no fear and is a super extrovert; he keeps us all on our toes. He is what some would say, “all boy.”   This is a brief bio of me and our circus; through everything, we have found joy in all circumstances. Although there are exceptionally hard days as we have endured much grief, God has always provided, and I am thankful for the life God has given us.   Questions we discuss: Life took an unexpected twist in 2016. Will you catch us up on your discoveries that year? While many of us were in the midst of changing schedules and suddenly homeschooling children in May of 2020, your family was receiving even more news. Will you share that with us now? What is life like for your family these days, as grief likely comes at unexpected times?   Thank You to Our Sponsors: Chick-fil-A East Peoria and The Savvy Sauce Charities (and donate online here)   Connect with The Savvy Sauce on Facebook or Instagram or Our Website   Please help us out by sharing this episode with a friend, leaving a 5-star rating and review, and subscribing to this podcast!   Other Episodes from The Savvy Sauce of God's Faithfulness: 17 Being on Both Sides of Forgiveness with Adelle Dickie 18 Clinging to Jesus as I lived Through My Worst Nightmare with Angela Braker 19 Grief and Triumph and God's Pursuit Though it All with Julie Locke Moore 20 Joy in the Lord Even Through Tremendous Loss…Twice with Rachel Faulkner Brown 62 Unexpected Grief and What Helped Me Through It Can Help You Too with Singer and Blogger, Brittany Price Brooker 78 Parenting the Prodigal Child And God's Desire For Redemption With Mother-Daughter Duo, Claire Stanfill and Tindell Baldwin 79 Radical Business and Radical Parenting with Gary & Marla Ringger, Founders of Lifesong for Orphans 83 Miracles of God with Founder of Midwest Food Bank, David Kieser 120 Our Story for His Glory with Mercedes Cotchery 134 Fashion Meets Faith with Shari Braendel 141 Rescued from Poverty with Norah Birungi 143 Prodigal Story: Sexuality, Drugs, and Scripture with Dr. Christopher Yuan 160 Unleash This Generation with the Power of the Gospel with Greg Stier 161 God Redeems with Hettie Brittz 162 Healing from Spouse's Sexual Addiction with Jennifer Roush 174 Stories of God's Upside Down Economy with Kristen Welch 208 Tremendous Testimony and Adding Spark into Your Marriage with David & Teri Sumlin 223 Journey and Learnings as Former Second Lady of the United States with Karen Pence 229 Escape from Modern Day Sex Slavery with Rachel Timothy Special Patreon 28 Re-Release: What to Do When You Don't Like Your Story with Sharon Jaynes 231 Stories Series: Faith Building Miracles with Dave Pridemore 232 Stories Series: Testify to Glorify with Richard Gamble 233 Stories Series: Surprises from God with Tiffany Noel Special Patreon Re-Release: Patreon 30 Story of Perseverance with Jenny Boyett 234 Stories Series: Redemption From Sexual Sin in Marriage with Garrett and Brenna Naufel 235 Stories Series: Ever-Present Help in Trouble with Kent Heimer 236 Stories Series: God's Power and Light with Jaime Farrell 237 Stories Series: Prodigal and Redemption with Renee Endress Special Patreon Re-Release: Patreon 31 Unexpected Story of Trauma, Anxiety, Adoption, and Hope with Bettina Stevens 238 Stories Series: God Delights in His Children with Brad Habegger 239 Stories Series: Experiencing the Supernatural with Jackie Coleman 240 Stories Series: God's Rescue and Covering in Parenting with Brenda Dugger 241 Stories Series: From the Mission Field, Experiencing God in the Little and the Big with Patty Sommer 242 Stories Series: He Gives and Takes Away with Joyce Hodel 243 Stories Series: Angel Encounter and Hearing from God with Mary Beth Zimmerman 244 Stories Series: Medical Marvels with Carolyn Henricks 245 Stories Series: Miracles Big and Small with Dr. Rob Rienow 246 Stories Series: Experiencing God's Tangible Love with Jen Moore 247 Stories Series: Exciting Adventures Follow Radical Obedience with Susan Zobrist 248 Stories Series: Discipline of Celebration in the Midst of Unexpected Loss and Grief with Jonathan Pitts Special Patreon Re-Release: Patreon 49: Story of Healing from Sexual Betrayal in Marriage: An Interview with Bonny Burns 249 Stories Series Conclusion: Now What? Living as Global Christians with Todd Ahrend of The Traveling Team   Gospel Scripture: (all NIV)   Romans 3:23 “for all have sinned and fall short of the glory of God,”   Romans 3:24 “and are justified freely by his grace through the redemption that came by Christ Jesus.”   Romans 3:25 (a) “God presented him as a sacrifice of atonement, through faith in his blood.”    Hebrews 9:22 (b) “without the shedding of blood there is no forgiveness.”    Romans 5:8 “But God demonstrates his own love for us in this: While we were still sinners, Christ died for us.”    Romans 5:11 “Not only is this so, but we also rejoice in God through our Lord Jesus Christ, through whom we have now received reconciliation.”    John 3:16 “For God so loved the world that he gave his one and only Son, that whoever believes in him shall not perish but have eternal life.”   Romans 10:9 “That if you confess with your mouth, “Jesus is Lord,” and believe in your heart that God raised him from the dead, you will be saved.”    Luke 15:10 says “In the same way, I tell you, there is rejoicing in the presence of the angels of God over one sinner who repents.”   Romans 8:1 “Therefore, there is now no condemnation for those who are in Christ Jesus”   Ephesians 1:13–14 “And you also were included in Christ when you heard the word of truth, the gospel of your salvation. Having believed, you were marked in him with a seal, the promised Holy Spirit, who is a deposit guaranteeing our inheritance until the redemption of those who are God's possession- to the praise of his glory.”   Ephesians 1:15–23 “For this reason, ever since I heard about your faith in the Lord Jesus and your love for all the saints, I have not stopped giving thanks for you, remembering you in my prayers. I keep asking that the God of our Lord Jesus Christ, the glorious Father, may give you the spirit of wisdom and revelation, so that you may know him better. I pray also that the eyes of your heart may be enlightened in order that you may know the hope to which he has called you, the riches of his glorious inheritance in the saints, and his incomparably great power for us who believe. That power is like the working of his mighty strength, which he exerted in Christ when he raised him from the dead and seated him at his right hand in the heavenly realms, far above all rule and authority, power and dominion, and every title that can be given, not only in the present age but also in the one to come. And God placed all things under his feet and appointed him to be head over everything for the church, which is his body, the fullness of him who fills everything in every way.”   Ephesians 2:8–10 “For it is by grace you have been saved, through faith – and this not from yourselves, it is the gift of God – not by works, so that no one can boast. For we are God‘s workmanship, created in Christ Jesus to do good works, which God prepared in advance for us to do.“   Ephesians 2:13 “But now in Christ Jesus you who once were far away have been brought near through the blood of Christ.“   Philippians 1:6 “being confident of this, that he who began a good work in you will carry it on to completion until the day of Christ Jesus.”   **Transcription**   Music: (0:00 – 0:09)   Laura Dugger: (0:09 - 2:07) Welcome to The Savvy Sauce, where we have practical chats for intentional living. I'm your host, Laura Dugger, and I'm so glad you're here. I'm grateful for today's sponsor, Chick-fil-A East Peoria.   Check them out online to place your order for dining or catering, or to fill out an application to join their friendly team. Visit cfaeastpeoria.com. If you've been with us long, you know this podcast is only one piece of our nonprofit, which is The Savvy Sauce Charities.   Don't miss out on our other resources. We have questions and content to inspire you to have your own practical chats for intentional living. And I also hope you don't miss out on the opportunity to financially support us through your tax-deductible donations.   All this information can be found on our recently updated website, thesavvysauce.com. And now, I'm pleased to share this episode with you that used to only be available to paying patrons.    My guest for today is James Jetton.   Mark and I attended the same family camp as James in 2022. I observed a father who was very devoted to his children, and one of his precious daughters was in a wheelchair, which was always by his side. He was so tender with his children, and I just assumed his wife was resting while he was attending to the family.   I did not learn of his full story until after camp, and it was through a mutual friend, April Siervo. But then, after she shared a bit more of their story, I immediately reached out to James to request that he share his faith and testimony with us today. Here's our chat.   Welcome to The Savvy Sauce, James.   James Jetton: (2:07 - 2:15) I'm happy to be here. I'm looking forward to talking to you and just kind of sharing how God has moved in our lives the past few years.   Laura Dugger: (2:15 - 2:24) You have already lived through so much, but let's just start here. When did Jesus initially draw you to himself?   James Jetton: (2:26 - 3:25) Yeah, I think that's like, you know, it's a big question, right? But also, it shouldn't be. I think the first time I really just kind of came to know the Lord, I was in the eighth grade.   I had a retreat, and in that moment, for me, it was a situation of— it wasn't necessarily for me, but also just trying to do the right thing. I grew up in Birmingham, Alabama, so I was in the Bible Belt. I was like, this is what we're supposed to do.   We're supposed to give our lives to Jesus. But I would say probably going into my senior year of high school, I had some moments just kind of alone at a beach, actually. I was like, what am I doing with my life?   And I believe that that was kind of the first one real moment in my life where I decided, I think I'm going to actually follow the Lord now and not just do this, just to say I'm doing it. And so that was really the first time I really felt the Lord draw me to him. And then, of course, as time goes on, there's all these other little moments throughout where he's continually staying close and bringing me back to him when I feel like I'm drifting away and that sort of thing.   Laura Dugger: (3:27 - 3:39) Thank you for sharing that. And you've written before on your blog that, I'll quote, one of the best decisions I have ever made was when I persuaded Kaetlin to marry me, end quote.   James Jetton: (3:39 - 3:40) Yeah.   Laura Dugger: (3:40 - 3:43) James, how did the two of you meet and fall in love?   James Jetton: (3:44 - 5:30) Yeah, so we went to college together. We went to Troy University. I vividly remember a time where she was getting out of her car, and she didn't know me at this time.   But I remember seeing her. I think I met her maybe once or twice through some mutual friends. I remember seeing her get out of the car and literally, I'll never forget this moment.   I was like, man, if I could just have a girl like that. And it stuck with me. And I think the first time we met, I think I made some comments that she wasn't happy about, about some fraternity guys that were in a different fraternity than me that I didn't think too highly of.   But I didn't realize in that moment that she was actually the sweetheart of that fraternity. And so, we kind of got off to a little bad step there. But I remember she broke up with another boyfriend.   That was part of the reason I saw her. And I was like, I could never have a girl like that. All the girls like that are taken.   And so, she broke up with her boyfriend. I remember her best friend called me and was like, “Hey, can I bring her over to y'all's house? Because she just needs to laugh”.   I was like, “Well, we can do that. We can make sure she laughs”. And so, I think from there, we just kind of, I don't know, just we continued to talk.   And for some reason, she liked me a little bit and I liked her a whole lot. And we dated for about three years in college. And when we got out of college, we got married in May of 2009.   And so that was kind of where life began to speed up a lot at that point. But that was the first time I'll never forget those moments. And then there's other things throughout.   But I remember seeing her in the parking lot like that girl.   Laura Dugger: (5:31 - 5:43) So, I love that. And OK, so married in 2009 and then children came a little while later. So how many children did you add to your family?   James Jetton: (5:44 - 6:28) Yeah, we have four kids. Our first child was born in 2013. So, after we got married, we lived back here in Niceville for a little bit but then ended up moving.   She wanted to go to PA school, and I was working a job I didn't care too much for. So, I was like, how quickly can we go to school? And so, we moved to West Tennessee where she went to PA school.   And I ended up going to school there, too, because she studied all the time, and I was bored. And I was like, I guess I should do something productive as well. So that was 2009 and we had a lot of fun.   We love to travel, did a lot of fun things. And then in 2013, we had our first child, Laken.   Laura Dugger: (6:28 - 6:39) And then if you fast forward, life took an unexpected twist in 2016. So, will you catch us up on your discoveries that year?   James Jetton: (6:40 - 13:07) Yeah. So, we, you know, so we had Laken in 2013. Then, we had another part of our - we did have a miscarriage between Laken and Isla who was born in 2015. But then we had Hattie who was born in 2016.   And Hattie's our child with special needs. And she was born in - all of our pregnancies where we used to joke with people that could have babies and just bounce right back and have these beautiful, wonderful pregnancies. And they loved it.   That was not us. Every single one of our pregnancies brought some challenge within it. And so with Hattie, my wife started swelling a lot and kind of found out she had some clotting in her legs.   And so, we ended up having to induce labor for her with that happening. And, you know, when she my wife was also a PA in the ER. So, she understood medical things way better than I did.   I was kind of oblivious to a lot of things. So, she would probably say it was a little bit more scary than I realized it was when she was giving birth. But when Hattie came, like in some accounts, it just kind of seemed normal.   But she was having some trouble breathing. And so, she was in our hospital. In order to go to the NICU, you have to kind of get transferred out to a smaller hospital.   And so, they were keeping her under observation that night. And her breathing wasn't really getting a whole lot better. And they did x-rays and stuff like that, but couldn't really find much.   And then there was a morning where we were about ready to load up and send her to the NICU. And Kaetlin went and held her. And when she went and held her, she started breathing better.   And she calmed down. And it was kind of crazy. It was genuinely like the love of a mother.   Just like this connection seemed to just calm Hattie down. But we ended up finding out later, one of the nurses was amazing. And was like, I think that she has a broken collarbone.   They didn't see it on the x-ray at first because of the way her chin was turned. And so, when they went back and looked, they did another one. And sure enough, she did have a broken collarbone.   So, at the time, we kind of thought that was kind of the reason for her distressed breathing and that sort of thing. And she had trouble latching and sucking. And what we kind of came to find out later is she had what would be called hypotonia.   Which is basically where the best way to describe it in layman's terms is like a floppy baby. Like you hold her up and everything just kind of flops. And I remember Kaitlyn going to her four-month appointment.   And her being very concerned like, “Hey, Hattie's not meeting milestones. And I think that this isn't going to be a good appointment”. And sure enough, the doctor agreed.   We've always had amazing doctors around us. And so, he agreed. And so, we got referred to neurology.   And another just cool story about how God just provides. One of my best friends growing up, his dad was a neurologist in Birmingham. And so, I called him.   And he's like, all right, I got it. You're going to be here next Thursday. I'm like, oh, okay.   When we were kind of told like it's going to be like three or four months before we can even get you into a neurologist. And so, like God just kind of provided that. And we started that journey of trying to figure out what's going on.   And anyone who's ever had a special needs child, especially when you don't know what it is. Because there was nothing we could have done to foresee this happening. What Hattie had was called DeNovo, like just completely her.   Didn't come from me. Didn't come from Kaylin. And there's no other kids with special needs in our family.   It was just something we couldn't have expected or planned or could have even seen or anything like that. And so just kind of going through a lot of different doctors and tests and eventually getting referred to Johns Hopkins in Baltimore. Because at the time they thought it might be a neuromuscular thing.   And so, from there, they're like, oh, we don't think that's what it is. But then we ran a whole bunch of genetic panels. And like you're just going through all of that.   It definitely there's waves, right? Like it's like you want an answer, but at some level you're afraid of the answer. So, like each time we would do testing stuff before nothing would ever come back.   And so, it was like a relief. Okay, well, good. It's not that one.   Okay. Not that one. But then you're still like, well, what is it?   And so, after we went to Baltimore, they did much more extensive genetic testing. We found out she had this genetic disorder, or syndrome is what they're calling it now called GNV1. And it's crazy rare.   Like at the time, there were only 64 known cases. It was discovered in 2016. So, there's chances that there's other kids out there with it.   I think now there's a little over 100 that they know of. We're part of like a Facebook group where there's some of them in there. And so that's what we got the diagnosis for Hattie.   And so, what that means, I guess, probably no one knows what GNV1 is. Not even doctors. We go to doctors like, oh, can you tell us what this is?   We'll do our best. But it just starts out as hypotonia and global delay, which means every aspect of her is delayed from speech to gross and fine motor movements and all that kind of stuff. And also like with kids with special needs, it doesn't seem to affect any one of them the exact same way.   And so, but the thing about Hattie is like she has an infectious smile. She has this joy that is unreal. Like anybody that meets her just can't get enough of her.   And that is true in so many ways. Hattie uses a wheelchair to get around and Hattie's expressive language. So, her ways to communicate is behind.   But she understands everything. I mean, everything, which is pretty amazing, is my understanding. Not all the kids have that ability to receive and understand things as well as she does.   But she is an absolute joy. We used to always say and still do that Hattie's going to change the world. And we know the fact she's changed my world for sure.   And we know she's changed many others. But yeah, I could keep going on and on. But where we are today, like genuinely that she is a purpose and a reason why I've got to get up every single day.   Yeah. So, she's pretty amazing. Like I'm just yeah, I could go on and on about her.   Laura Dugger: (13:08 - 18:15) I think you described her so well with an infectious smile and joy is the word that comes to mind when you see her. Yeah. And now a brief message from our sponsors.   I want to say thank you to our longtime sponsor Chick-fil-A East Peoria. I hope that you've already downloaded the Chick-fil-A app. Because did you know that with the app you can skip the line and have food ready for you when you arrive?   This is one of my favorite options when I'm taking my four daughters to Chick-fil-A East Peoria. Download the Chick-fil-A app today and start earning points toward free rewards that are fully customized to your preferences and tastes. Chick-fil-A was named as one of Glassdoor's best places to work in the nation.   That's a huge honor. And one team member even wrote, no comparison. This is a great job for a first job, extra money or for career advancement.   Such a loving environment, great management and fair pay. Chick-fil-A believes that the local and involved ownership ensures fostering an environment where you are known, challenged and cared for. So, if you're looking for a wonderful place to work, visit Chick-fil-A East Peoria or fill out an application online today at cfaeastpeoria.com.   Are you utilizing Savvy Sauce Charities to full capacity? Other than our special Patreon re-release episodes, our content is now available in video form in addition to our audio only. And we have written transcriptions for every episode.   Visit our website today, thesavvysauce.com, to access all these forms of interviews. And while you're there, make sure you sign up for our email list to receive encouragement, questions and recommended resources about once a month to promote your own practical chats for intentional living. I also want to remind you about the financial side of Savvy Sauce Charities.   As you know, we recently became a non-profit, which means all your financial support is now tax deductible. There are multiple ways to give and we would be so honored if you would share your financial support with us so that we can continue producing free content that is accessible to the general public. Your money will go to support creatively getting the gospel message of Jesus Christ to the nations as we continue to share the good news on every episode.   And I say this is reaching the nations because The Savvy Sauce podcast is downloaded in all 50 United States as well as over 100 countries around the world. Your financial support also supports practical needs such as aiding our team to continue producing helpful content that is practical and uplifting and always pointing to Jesus. Your financial support furthermore will help us continue to expand our reach and secure future projects we have planned for this ministry.   If your ears are hearing this message right now, I am specifically asking you to give. We are so grateful for any amount and our team will continue to seek to be good stewards of the gifts offered to us. So, if you want to write a check or set up an ongoing payment with your bank that delivers a check to us each month, this is the most beneficial way to give because no percentages are taken out for processing fees.   You can make your checkout to: Savvy Sauce Charities, P.O. Box 101, Roanoke, Illinois, 61561. Additionally, with our new website, we now have a donate button. There are processing fees that we cover for these donations, but we wanted to offer listeners a seamless way to share their finances with us when we share our content with them.   So just visit thesavvysauce.com and find the donate page under the tab support. Another way to find it is simply type in donate to the search bar on our website and just click the first picture shown. We are all about sharing around here, sharing resources, sharing joy, and sharing the good news about Jesus Christ.   We ask that you also will share by sharing financially, sharing The Savvy Sauce podcast episodes, and sharing a five-star rating and review. You can also share any of our social media posts on Instagram or Facebook. We are grateful for all of it, and we just love partnering together with you. Now, back to the show.    In a different season, when many of us were in the midst of changing schedules and suddenly homeschooling our children in May of 2020, your family was receiving even more news. So, will you share that with us now as well?   James Jetton: (18:16 - 22:36) Yeah. We did have our fourth kid, Ryder. He was born in 2018, and he is a wild man.   My wife and I used to always say, or people would tell us, you'll know when you're done. But we had him, and we were like, okay, we're broke. We're done.   No more. But he's awesome. But yeah, the move forward to then, you know, that COVID stuff was really hard.   It was really hard. I was working for a church, and I do sports and rec ministry, and also I was doing student ministry at the time. And so, for me personally, like, things just kind of got shut down.   No one was doing sports leagues, and student ministry looked weirder than ever. And then my wife, she was working in the emergency room as a PA, and so she was facing everything head on. And so, I guess that kind of started in March.   It's funny, just to kind of back up a little bit. We felt prior to that, probably February or March of that 2020, when things were kind of like exploding, we just felt the Lord doing something in our lives. We felt like He was preparing us for something.   We felt like it was going to be something just amazing. But then as we moved forward to try to understand what God is doing, what He was telling us, in May, my 4-year-old, she had her preschool graduation. And I'll never forget this day.   My wife was a go-getter. She's tough. She's strong.   And we had a super weird COVID graduation for Isla, my 4-year-old. And it was weird because it was a drive-through graduation, so we had to get up there early and go do it. So, my wife also, she would do work night shifts so that she could be home with the kids when I couldn't be there.   And so, it wasn't uncommon for her to have to sleep in some. But this was like she hadn't worked the night before, and she hadn't worked. And so, we'd been off for two days, but she was just so exhausted.   She had this terrible headache that morning. And for her to say, like, I can't go to the graduation, that was like, there's something significant here. And I told her, like, she had gone to the doctor about a week before and got on some antibiotics, but it wasn't doing anything.   And I was just like, hey, I think it's time to go back to the doctor because you're not any better. And I've got to take these kids to this graduation. So, I loaded up all the kids.   We went to the drive-through graduation. While I was there, she called and said that her sister was going to take her to the emergency room. So that was a long day.   At that time, COVID was full on, so she couldn't have visitors. No one could come in with her. She had to be dropped off and go inside.   One huge plus in that for our specific situation is that she was taken to her own emergency room. So, she still had her friends and what she would call family there as well. And so, she dropped her off.   My sister-in-law dropped her off and just kind of waited in the parking lot until we figured out what was going on. So, it kind of went throughout that whole day. And I remember that night, the school was doing another virtual graduation where they showed pictures and that sort of thing.   And she texted me and said, I need to talk to you now. I was like, okay, like right now? Because I'm home alone with all four of the kids.   She's like, yeah, and I need you to get away from the kids. I was like, this doesn't sound good. What could this be?   And so, we FaceTimed, and that's where she told me they think I have leukemia. And so then as things started speeding up, we sent out a message to our church asking for prayers. From there, I put the kids to bed.   I drove to Pensacola. She got transferred to Pensacola, and we started treatment there for leukemia. So that was what happened.   That was the big moment in May. And then from there, there's a whole lot more. And so, I'll share as you wish.   Laura Dugger: (22:37 - 22:54) Wow. Thank you for catching us up to that point, James. I can't even imagine the initial devastation that comes.   And as your journey unfolds, I remember seeing a post about leaving your light on.   James Jetton: (22:54 - 24:24) Yeah. Like I said earlier, my wife always did the night shift. And so, I always left the light on for her when she was at work and then turned it off when she came home.   And so, yeah, so early on, I said that I'm not turning the light off until you come home. And so, during that time, the first treatment, it doesn't seem like a lot now because she was in the hospital so much. We didn't know how long she'd be in there.   But the first initial treatment, they're like, you're going to be in for three weeks. And so, I knew that she wouldn't be home for three weeks. And I guess this is me just kind of realizing that was a long time for the kids.   I remember talking to a friend of mine who was leading a small group of high school boys. And I remember him telling them, like, how hard do you think it would be if your mom was gone for three weeks? I was like, yeah, it's not easy.   But so. So, yeah, so that was that was the reason. Just like my wife, one, she was a light in the midst of all the darkness that she was having to face.   And I just wanted to make a point that like, hey, we're leaving this light on for you until you come home. And in a lot of respects, you know, she did go home. Long, long story.   But, yeah, that that was the reason for the light.   Laura Dugger: (24:25 - 24:34) So, well, and the way that you describe her, it sounds like our mutual friend April said her joy was just out of this world.   James Jetton: (24:34 - 24:36) Yeah, that's true.   Laura Dugger: (24:36 - 24:49) It sounds like maybe the both of you share that, but you were not entering into a joyful season. So, what did the next few months and year even look like?   James Jetton: (24:49 - 30:47) Yeah. So initially, when things went down, my wife and I agreed that we would not let our kids lose both their parents. And so, I tried to make it a point to be home at night.   So, when we were in Pensacola, like I would stay with her some nights, but I would also be home at night to put the kids to bed or I would put the kids to bed and I'd drive over that night and come back in the morning or be with her during the day. Like, you know, it was just crazy stuff. One, you know, it happened at the end of the school year.   So, we have all the kids at home. We didn't get to send them off to school. We were blessed to have an amazing college student.   It was one of Kaetlin's girls that she got to mentor when she was in high school. She was an amazing girl. She decided she would be like our nanny that summer.   And so, she was with our kids all day, every day. So, I could go and be with Kaetlin during the day and come home at night. And so, we went through that.   We were here and we did the treatment in Pensacola. It didn't work. And so, the next step at that point was like, well, what are we doing now?   And on a Thursday, the doctor was like, I think we need to go to MD Anderson. We'll see if there's a spot. And then on a Friday, they had a spot.   And then on Monday, we were in Houston at MD Anderson. I went to MD Anderson with her. You know, COVID protocol there still.   I could only be with her for 14 days and inpatient. And then I had to leave as an inpatient. So, I can only go with her for 14 days in that initial time.   And so, we went there. She started a treatment plan. We found an apartment.   And then I left. And then her dad came. And her dad was huge in a lot of this stuff and was able to allow us to do things like me and be with the kids.   And so, I think I stayed there for 10 days. And then he came over to stay with Kaetlin to take her back and forth to the hospital, just receiving treatment. And then I came home, and I came back to Niceville.   And that was during the summer. July, we were at home. We stayed in Niceville just kind of waiting to see, like, is Kaet going to be there longer?   Or is she going to be coming back here? And that was a wild summer. And this is what I think I would tell a lot of people that are going through hard things.   Like just because you're going through hard things doesn't mean there's other hard things. They're just a part of life. And, you know, when you have four kids, stuff happens.   You know, like we had one of my daughters, Isla, she had to have eye surgery that summer. While Kaet was in Houston. So that was an interesting thing.   My four-year-old son, he busted his head open on the back of a step going outside. So, he had to have some stitches in his head. He's the second that has had stitches in our family.   And he was the youngest. So, then the treatment, the goal was to get her to a place where she could do a bone marrow transplant. And so, we got, they got her to that point.   Her leukemia cell counts were low enough that we're ready to do a bone marrow transplant. And at that point, you know, we decided we're going to move to Houston. Everything was virtual at that time.   And I just couldn't see any reason why we couldn't all be together in Houston. And so, we found an apartment, we hunkered down. It's a two-bedroom apartment.   We built some makeshift bunk beds. And so, we moved there in August. And the community we have here was unreal.   The support that we have. Like I didn't, we didn't have to make a meal for, I felt like six months, I think. Like it was just crazy.   And people were allowing it and giving us money. So, we didn't have to worry about these kinds of things and what we're doing. And from moving packing boxes, like, I mean, I can't, it's just unfathomable.   All the different things that were put in place for us to do, to do what we did. And I don't think it would have happened without the community that came around us and our church here was great, but I've got to see The Big-C Church. And, and, and it was, it was amazing.   And so, we ended up, we all moved to Houston, and we lived in a two-bedroom apartment. Part of that story is like, you know, it's like, all right, we're doing this. And then talk about kids.   My four-year-old, the one that had also had the eye surgery, she had broken her ankle on a scooter. Like a week before we're going, it was like, are you kidding me? How is this happening right now?   But we had some great friends like, you know, when your wife is involved in the middle of the medical world, it makes access to doctors and stuff a lot easier when you're in a small town, like we are. So, they got it taken care of, got her in a cast. I was like, yeah, but we can't return with this hard cast.   We're going to Houston. He's like, all right, we'll get her in a hard cast. And we'll put her in a boot for the rest of the time.   So, we moved there. And you know, the dreams of like riding scooters around downtown Houston and doing all this kind of stuff kind of went away a little bit with the kid. And so, he, but there was a pool there.   So, we went swimming, she could swim. And so, we, we just made the best of what we had. Like we, we had a lot of good memories in that little apartment, even though it was, it was tough.   I remember, we, Halloween wasn't too long ago. We had our own little Halloween party in that apartment where we all dressed up, even Kaet. Cause she ended up getting her bone marrow transplant that time.   And another aspect of where dad was so important is when you get in the bone marrow transplant, you cannot leave, and you can have one guest. And so, her dad came and he stayed with her. It was about 30 days of bone marrow transplant.   And so, he was there with her so I could be with the kids, doing the best I can with that virtual school and, and managing Ryder and Hattie in the midst of trying to do school work with the kids. It's nothing I ever want to go back to.   Laura Dugger: (30:48 - 31:03) Well, and not to mention you appreciate The Big-C Church, but Houston was not your long-term community. So, being here in this new place and all of these transitions, what were the results of her bone marrow transplant?   James Jetton: (31:04 - 40:17) Yeah. So, the bone marrow transplant, it ended up working. She went into remission and so we get to come home Thanksgiving of 2020.   We came home and that was awesome. It was like a huge homecoming. Finally got back home.   She's, she's in remission. We felt like we'd beaten this. We, you know, we got that Christmas here and we were back home.   We even, our family always loves to go, has always gone to North Carolina for vacation every year. And we didn't get to do that. But so, it was like, now we're going.   And so, in January we're like, all right, we're going kids. It was just me and the kids and Kaet and we wanted to go see snow. So, we went up there and we found a place to stay.   It was an awesome trip. Loved it so much. We, when we had to check out of our place, we found another house so we could stay in for a few more days.   And so, you know, at that time though, when we were doing that, she was kind of having these red bumps kind of popping up over her. We didn't really know what it was. It could have been a reaction.   We couldn't figure it out. Saw some doctors here locally. No one could really figure out what it was.   And I think fast forward, what we found out probably, I think it was February. She came out of remission and that was kind of the beginning signs of her coming out of remission. And so that's where, life sped up.   Like, I mean, if it wasn't already fast, it was, it was just unreal. It was like a whirlwind like it was because she had to fly to Houston to go and see her doctors. And so, she was in Houston by herself when she found out that she had come out of remission, and they were going to start immediately.   So, she stays, and she flies over on Friday and on Monday they got her back doing her treatment. And so, and I was like, well, it looks like we're moving to Houston. And I was like, but this time we're not staying in a two-bedroom apartment.   It's like we're going to make this a little bit more manageable for us. So, we had some great family. Kaetlin actually had a cousin who lived in Houston.   We found a house inside their neighborhood that we could rent. And this was, you know, more, more provision that he just continued to show. We found this house in like a week and we had people from our community boxing up everything in our house.   He's gotten a truck, and we thought that we'd all get everything in one truck. But we didn't get everything in one truck. We'd even hired the movers to load up the truck.   They couldn't get it all in there. So, I was like, y'all told me that it would all fit on this truck, but now it's not. And it's Friday at like 5 p.m. when we were supposed to leave tonight. So, we're not leaving. But my brother came down. I had another one of my best friends come down and they were like, we got to go, we're going to make this happen.   So that next morning, I'm not kidding. When there was like 20 to 30 guys in my house, a brother had gotten the truck. I hadn't even, they left early to go with the truck.   I'd come. And I was at the house with the kids at a friend's house. And when me and the kids showed up, these 30 guys had already loaded up the truck and we were ready to go.   Guy came and dropped off a big spread of McDonald's for everybody. We prayed over us and we headed out that morning. And so, it was just, I mean, just crazy that, you know, in one week we packed up a four-bedroom house, loaded up two trucks and drove to Houston and we're now unloading at a new house in Houston.   And, and that's where we were for a while. That was where Kaetlin, then we went back into the treatment more aggressively trying to get her back to remission. And so that was, when we moved there in March of 2021.   And that was kind of our place for a while. We actually thought we'd be there for a real long time. Kids had started school there, trying our best to get connected community there, but it's difficult, especially when you've come from a place where you feel so connected and then you're moving somewhere new where you don't really know anybody.   And then you're moving there in a time where the whole town shut down. It was tough, but we got the kids back in school. We tried to start getting them back into normalcy of life.   And there's all these new trials when you're going through this stuff every day, it seems like there's a new trial. MD Anderson is amazing. They treat each patient. It's like an individual.   So, every plan they have is just specifically for that patient. And so, they were going to try to do this CAR T-cell treatment. So, we'd kind of gone through the whole summer, and then we get to the point where she's going to do her CAR T-cell treatment.   Now, you know, we, we were hunkered down with this COVID stuff. Like we didn't, we didn't do much. We got really good at DoorDash and grocery delivery.   And we, you know, we masked up everywhere we could because Kaetlin's system was so immuno-compromised and we had done what we had thought was a very good job of keeping her safe, keeping everyone safe. Well, and then she got to the point where she was ready to start this new trial with CAR T-cell treatment. And she gets admitted that night and every time they go in and they give her a COVID test, well, that night she had COVID.   And it was, it was like, what? And she didn't feel bad. Her dad had gotten it too.   Like we, and I, so I remember getting that, it was like one o'clock in the morning. I was asleep. I remember it like blowing up my phone.   And I was like, I didn't realize it until later. And I talked to her. And that was definitely a tough conversation because she had to like get moved, packed up and moved out and moved to a different place and then treatment for the COVID stuff.   But the crazy part was, and it was kind of, you know, I wanted to get frustrated about things I could, but like, she had zero symptoms and she had just tested positive. And so, the next morning we all had to go get tested. And it was just the weirdest thing.   I know that COVID has been so devastating to so many people. But in that moment for us, it was like, we don't like, I was like, I ran nine miles yesterday and now I'm positive for COVID. I don't.   And so, but what it did was it kicked her out of the trial that she was on. And so, then she had to come home. The next process was just kind of getting her ready for that same thing.   Basically, what her doctor did was like, I'm not taking out, you're going to get kicked off the trial, but I'm just going to make you my own individual patient. We're going to do it that way. And so, we had some, we had some pretty high hopes for this.   Doctor seemed pretty optimistic about this plan. And so, we had been renting our house in, in Niceville. And with this new plan, I would have had Kaetlin there for like three years.   And so, we were like, you know, do we really want to rent our house anymore? It's like, no, we don't. All right, well let's sell our house.   So, we sold our house, and it sold in like less than 24 hours. And it's like $25,000 over asking price. It was like, well, okay, God, I feel like that's what we're supposed to do.   And so, she went in to get that treatment. And, and, uh, unfortunately, uh, we found out that didn't work. Uh, it was like, well, she can't remember coming home and saying like, well, I'm ready.   I want to go back home. I was like, what? We just sold our house.   We don't have a home right now. But God always makes a way and you always provide always. Um, and so we, you know, I was like, all right, we want to go home.   We're going to go home. And at first I was being very logical. I was like, well, let's let the kids finish out the semester.   Cause this was like around Halloween is when she realized it didn't work and we're going to come home. So, we were able to come home. We had some amazingly generous friends who they got us a private flight to come home for that Halloween.   And I guess when we were there, um, that's where we really just decided we need to be back. And, and so she, when we went back to talk to her doctors about managing her leukemia remotely. And so that was what the plan was.   So we, we moved back that Thanksgiving, uh, with all of our stuff and we were looking for a place to stay. It was actually kind of a fun month. We were living on the beach for a couple months or really from Thanksgiving to right before Christmas.   We had some pretty awesome things come available. We were able to live in a house on the beach. And so that was, that was mine and my wife's always kind of like a special place.   And so, we love the water, and we love the beach. And so that was an awesome place for us to be. And so, uh, coming back, it was tough.   She was getting out of the hospital a lot just with fevers and stuff like that. And then we got to have Christmas here that December. And then January 9th of this past year, she, she, uh, eventually passed away.   We weren't expecting, I mean, we knew that there would be an end, but I don't think we could have expected it to, um, happen then. And I think we kind of thought we'd have a little bit more time, but we didn't, but we were thankful. I'm thankful for my wife.   It was like we got to get back now because we knew that when an issue did pass that we needed to be in our hometown and not in Houston, where our community was much smaller.   Laura Dugger: (40:18 - 40:27) So, yeah. And so, you're together, you're celebrating Christmas. And then things suddenly turned unexpectedly.   James Jetton: (40:28 - 40:28) Yeah.   Laura Dugger: (40:28 - 40:31) And that led to losing her on January 9th.   James Jetton: (40:32 - 44:59) Yeah. You know, nothing really happened like, you know, in that leukemia world. And you know, a lot of cancers that give you like, you know, a prognosis like, you have three months, you have four months full, but blood cancer is very different.   And it kind of exacts you and, and there's no way to really know for sure, like, is this going to work or how long do we have and that sort of thing. And she was just in and out of the hospital so much. When we came back home, when you have leukemia, anytime you have a fever above a hundred point four, it's like you're immediately going to the doctor.   And so that's kind of how, you know, when she went in, like, there's still kind of an expectation that she would come home. But then those last few days, like, I just, I vividly remember as we're trying to figure out what to do, we're going to, are we going to go to a new treatment plan or we're going to try something else? Or, or is this kind of the end?   And her doctor here, he said, there was a plan that we possibly could have done, but he was like, they're saying this got a success rate of like, whatever, nine of 10 people went into remission with it. He's like, but when you look closer, they were only in remission for four weeks. And he was like, is this what we want to do?   Cause chemo just, it wipes you out. And it's like, there's no way to continue to live like this. But she, Kaetlin, she was, she just had a way of bringing a peace over everybody.   She had a way of like knowing exactly what everyone needed, I guess, in some respects. Cause I remember leaving the day we decided we would not do the treatment plan. And I came home, like I said, I always try to be home to put my kids to bed.   She said that the night before it kind of, she went downhill fast. She got up and walked around the hospital with her dad and told her dad like, “Hey, I think I'm going to do, I think I'm going to do it. I'm going to do the treatment plan.”   You know, I've talked to him about this, but I feel like that was almost like the piece he needed to go home. You know, when she passed, it was like, it was beautiful. Like it was, it was such a blessing that she was in her home hospital and that the doors, it was like a revolving door.   I remember Kaetlin told me once, she said, “when I pass or when I'm in the last days, don't tell anyone that they can't come see me.” And so, we were trying to figure out how we're going to do this. And I was like, well, she said that anybody who wants to come see me, let them come see me.   And so, we put a word out and there was like a revolving door of people just coming in and out of the room all day. Like the doctors, the ER told the front desk people, like, you know, technically, I guess you're only supposed to have like two visitors or something because of the COVID things. And she was like, anybody that comes in and says they want to see Kaetlin Jetton, you say, “Go on up”.   So it was, it was pretty awesome seeing all these people come in and see her. And we had already gotten to see the impact that she had made on so many people's lives for the past couple of years, but it was cool to see them all there doing that. And I remember the night she passed, I leaned over, I was heading home and two of my best friends since the ninth grade had come down and they were at the house with the kids and I was coming home to put the kids to bed.   And I leaned over and gave her a kiss and I said, don't wait on me. It's like, it's okay. It's time to go home.   And sure enough, that's, I left that night and I got a phone call about 11 from her dad and she had passed and that, and I think that, you know, in some respects, it's like, should I have been there? I was like, but I think that also was like, no, Kaet wanted you to be with your two guys. And Kayla knew that her family would be there with her.   And she did exactly what she wanted to do. You know, she always had a plan even from her like celebration service. She had everything written out.   Who's going to speak, what songs are playing, when are we doing this? And so it was, it was, you know, it was pretty cool seeing how many people just came in and out and how she just kind of felt like she knew what she was doing, even up in the last days. So.   Laura Dugger: (45:00 - 45:55) Do you love The Savvy Sauce? Do you gain anything when you listen? Did you know that the two ways we earn money to keep this podcast live is through generous contributions from listeners and from our paying sponsors.   That means we can promote your business and you're still supporting The Savvy Sauce. It's a win-win. Please email us today at info@thesavvysauce.com to inquire about pricing for sponsoring each episode. Thank you for your consideration.    Well, James, your perspective is incredible. And yet I'm so sorry, such a deep loss for your whole family.   And what is life like now for all of your family these days? Cause it's still very recent. And I'm wondering if grief still comes up at unexpected times.   James Jetton: (45:56 - 50:49) Yeah. You know, it's, you know, it's a day-to-day thing, I believe. I don't, and grief is certainly something that sometimes you don't see it coming.   And I'll say, I love bragging on this community. I love bragging on this town so much. So, my kids, they're all in school, you know, and I'm bragging on my kids too.   After she passed, the kids got to stay home for a couple of weeks, but then it was time to go back to school. My two girls go to one school where actually Kaetlin went to school from kindergarten all through. So, I felt like that was a very special thing for her and the kids could go to the same school that their mom went to.   But then Hattie goes to a different school because of her special needs. And then Ryder goes to a different school. He's in preschool.   And so, after she passed, like, so it was complicated in the sense of, I've got to get Hattie to school at 7:30. I've got to get Lincoln out of school by like 8:45 and then Ryder can go in before 9:00 a.m. So, I would usually drop him off on the way. But I say, I'd say like, what does life look like?   Well, after she passed, I knew like, how am I going to make this work? And that semester, there was somebody in my house every morning at 7:00 a.m. to sit with the kids, help with breakfast, and help finish getting them ready while I could take Hattie to school at 7:30. And then I would come back home and after they finished getting ready, then I would take them to school. So, I had someone in my house every morning at 7:00 a.m. after she passed, which was, you know, they were doing it for the kids, but they were doing it for me too. I knew that I couldn't just lay in my bed and let people just come on in and take care of my kids. Like I had to get up, take a shower, look like I'm somewhat presentable and go on. And that's kind of how that last semester was, just community and people with meals and then through all that, trying to get them engaged, get them back into doing some things that they love to do.   And yeah, I like to brag on my kids in a lot of ways, this perspective kind of dawned on me in the past couple of weeks of like, I sent them back into a new school where they know very many people. Everybody knows them. Not everyone.   I don't know everybody. And they had to go and do that a few weeks after their mom passed. Here I am trying to stay away from people and not have a whole bunch of conversations, but yet the kids are stepping up and doing their thing.   And man, it's just, it's pretty inspiring when I think of it in that respect as well. Nowadays we are blessed that we get to have a nanny and it's, that's a whole cool story in itself. And that she worked with me in student ministry, and I'd actually left to go be a nanny for some other people in Nashville.   And I was texting her trying to figure out, “Hey, I need some help. You got any friends down here that want to be a nanny? Cause it's hard to find.”   And she's like, “Actually, I would love to come back and do it.” And that was just a huge blessing. Cause it was like, at the time of us having all these new things, I was able to be able to have somebody that the kids already knew come in and be there.   And so, she helps in so many ways and allows the kids to do their tennis and their soccer and gymnastics or whatever it may be. And it allows me to get to, coach them and be a part of that, those aspects of life, which I love doing so much. And so, she's really helped.   So, in our day to day now, like it, it's a lot of moving pieces. I mean, just last week, we got to go to a widower's retreat and there was never a worry, never worry about who's taking care of the kids, that they're getting to where they need to be. So, it's a genuine, like I get to see how a village truly takes care of the kids.   And yes, there are days and it's hard. And some days it just kind of sucks and it sucks for them. It sucks for me.   But I have gotten to see how God still shows out through the difficult moments and how he still provides no matter how far away I am or how close I am. He still continually provides. And I know that, and I know that he will not let us down.   It's one day at a time. And as we approach these new seasons, there's always new seasons. You talk about grief and things pop up.   I think that holidays will bring up stuff they already have in some respects and my wife, you know, she was a medical professional. So, when kids get sick, it's different now. We go to the doctor more often because mom's not here to take care of them and call in medicine.   But I think that we do sense a void in that when kids are sick and that sort of thing. But, today, like things are okay. We're doing all right.   Laura Dugger: (50:50 - 51:07) Well, and James, you were a journalism major and you're a very gifted writer. So where would you direct us to get to read more about your family and stay current and hopefully find ways that we can further support you?   James Jetton: (51:08 - 52:18) Well, my wife and I, we started a blog called Our Hands Go Up, and it's OurHandsGoUp.com. And that's formed out of, started with Hattie. That's where the blog started because Hattie, we talked about that joy that she has, but our hands will always go up.   Like her hands go up all the time and it just seems so appropriate. And the picture of hands going up, there's so many things that go to that with our praise to God, our vulnerability and our sides. And there's just a lot that comes through that anyway.   But yeah, Kaetlin started writing on that and I wrote some in that. She spearheaded it because she's way more organized and detailed than I am. So, it looks a lot prettier than what I would have done, but here recently, like I've felt a calling to bring it back and revitalize it.   So as of right now, like there's, my wife wrote a lot, and she still has writings that she never shared with anybody. So, I've started revitalizing it by sharing some of her writings, but I will be writing in there as well. So that would probably be a good place or even, and then my, just my social media, James Jetton, you can always see some crazy stories of my kids.   Laura Dugger: (52:21 - 52:34) Oh, wonderful. We will link to both of those in our show notes. And are there any practical needs that you do have at this time or any specific prayer requests you would like to share with us?   James Jetton: (52:35 - 53:26) You know, I think the specific prayer requests are just for me and for my kids. So, things are going to look different for them for sure. And I know there's going to be some hard moments.   So, I guess the prayer would just be, you know, provision as God's always provided. And, you know, when I say that, I don't just talk about it in like a material way, but like He seems to provide us with feelings, emotions, people, support, all of that. And so just provision for my kids and just encouragement and support for them as we've kind of walked through these, these new firsts for the kids and, and that it will just, they will still have, find the joy that we always talk about choosing and, and that my wife did so well that we will continue to find that joy through these more difficult days ahead for sure.   Laura Dugger: (53:26 - 53:58) Yes, Lord may it be so. Well, James, you clearly just have so much wisdom to share and I appreciate you walking through so much of your personal journey. And I know that you also do have a lighthearted personality and we're going to end on a lighter note because you may know that we're called The Savvy Sauce because Savvy is synonymous with practical knowledge.   And so, as my final question for you today, what is your Savvy Sauce?   James Jetton: (54:01 - 54:51) You know, my Savvy Sauce, it's just, it's one day at a time. I think that we get overwhelmed with, you know, I joke with people, like it's a stupid joke. But hey, if God wanted to give us more than one day at a time, He would. So, we only get one day, and He doesn't give us two days at one time.   You know, just taking things as they come one day at a time. We all have our goals. We all have our plans, our dreams and aspirations, but leaving space for the Holy Spirit and how God moves is critical.   And when you're walking through grief and you're walking through hard stuff, like thinking about too much out there in front of you can be debilitating. And so just focus on what your next step, just take one more step. We can always take one more step.   And so just kind of day at a time and just take one more step.   Laura Dugger: (54:52 - 55:08) James, thank you for your faithfulness to Kaet, your faithfulness to our Lord, your faithfulness to your children. And we will all be praying for each of you in this coming season and beyond. And just really grateful for you being my guest today.   James Jetton: (55:09 - 55:26) Well, I'm really grateful to be here. This is great. I'm thankful for the chance to just share her story and share our story.   I feel God has just moved and worked through us in so many amazing ways. And anytime I can get a chance to share how God has moved and worked, I'm thankful. So, thank you for having me.   Laura Dugger: (55:26 - 58:42) It's been an honor. One more thing before you go. Have you heard the term gospel before?   It simply means good news. And I want to share the best news with you. But it starts with the bad news.   Every single one of us were born sinners, but Christ desires to rescue us from our sin, which is something we cannot do for ourselves. This means there is absolutely no chance we can make it to heaven on our own. So, for you and for me, it means we deserve death and we can never pay back the sacrifice we owe to be saved.   We need a savior. But God loved us so much, he made a way for his only son to willingly die in our place as the perfect substitute. This gives us hope of life forever in right relationship with him.   That is good news. Jesus lived the perfect life we could never live and died in our place for our sin. This was God's plan to make a way to reconcile with us so that God can look at us and see Jesus.   We can be covered and justified through the work Jesus finished if we choose to receive what He has done for us. Romans 10:9 says, “That if you confess with your mouth Jesus is Lord and believe in your heart that God raised him from the dead, you will be saved.” So, would you pray with me now?   Heavenly Father, thank you for sending Jesus to take our place. I pray someone today right now is touched and chooses to turn their life over to you. Will you clearly guide them and help them take their next step in faith to declare you as Lord of their life?   We trust you to work and change lives now for eternity. In Jesus' name we pray. Amen.   If you prayed that prayer, you are declaring him for me, so me for him. You get the opportunity to live your life for him. And at this podcast, we're called The Savvy Sauce for a reason.   We want to give you practical tools to implement the knowledge you have learned. So, you ready to get started? First, tell someone.   Say it out loud. Get a Bible. The first day I made this decision, my parents took me to Barnes & Noble and let me choose my own Bible.   I selected the Quest NIV Bible and I love it. You can start by reading the book of John. Also, get connected locally, which just means tell someone who's a part of a church in your community that you made a decision to follow Christ.   I'm assuming they will be thrilled to talk with you about further steps, such as going to church and getting connected to other believers to encourage you. We wa

A Show Director and writer whose clients includes Disney, Disney Cruise Line, SeaWorld, the Tribeca Film Festival and the World Science Festival. Other clients include the BBC, TLC, ABC, Carnegie Hall, Scholastic Publishing, South Africa Tourism, Macy's Thanksgiving Day Parade and Light the Night for the Leukemia and Lymphoma Society of New York.  As an improviser Greg has worked with some of the premiere sketch comedy troupes in the country including the Brave New Workshop in Minneapolis and the Who, What and Warehouse Players at Disney's Comedy Warehouse. He also co-produces and appears with the MAC Award Winning Ensemble of Broadway's Next Hit Musical. Triggs regularly teaches improvisation, trust and teamwork seminars for The Disney Institute, the American Council of Mayors, Microsoft, the United States Navy, and Johnson & Johnson Pharmaceuticals. 

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Cases continue to rise in Texas’ ongoing measles outbreak. Experts say they know how to stop the spread. What’s preventing that?One priority for Lt. Gov. Dan Patrick this legislative session is clawing back the state’s legalization of hemp-based products. Where that effort stands.You’ll need a REAL ID to travel by air starting May 7. How […] The post Living near oil and gas wells linked to childhood leukemia appeared first on KUT & KUTX Studios -- Podcasts.

There's a whole lot of gratitude, kindness, and community comin' your way in this episode...Tressa sits down with good friend - and fellow Jefferson Award recipient - Bradley Wilkins to chat about all he does in his community and why connecting with his neighbors is so important to him. They also talk about Bradley's current campaign as a candidate for the Leukemia and Lymphoma Society's Visionary of the Year. And Tressa and Don read (so many!) notes from the Kindness Crates that made a stop in the Carlynton School District. The notes were originally read as part of Carlynton's 3rd annual Women's Empowerment Summit, which Tressa emceed. Donate to Bradley's LLS campaign at Tressa's page: https://pages.lls.org/voy/wpa/pgh25/tgloverLeukemia and Lymphoma Society website: https://www.lls.org/https://www.yinzaregood.com/Want to learn more about the podcast, including all of the guests who've been featured thus far? Check out our website: https://www.yinzaregood.com/FOLLOW US on social media! Instagram: @yinzaregood Facebook: @YinzAreGoodHave a story of GENEROSITY or KINDNESS to share with us? Want a KINDNESS CRATE dropped off at your business or school? Email us at yinzaregood@gmail.com

Personalized therapeutic approaches for the treatment of chronic lymphocytic leukemia (CLL), guided by shared decision-making, can improve outcomes by aligning treatment with a patient's unique clinical profile, preferences and goals. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on CLL management and treatment strategies. In this episode, CANCER BUZZ speaks with Christopher Nelson, ACNP, MBA, certified oncology nurse practitioner at Avera Medical Group Oncology & Hematology, to explore the importance of shared decision-making and patient communication in CLL. Additionally, CANCER BUZZ speaks with Meghan McGrath, MSN, RN, AGACNP, clinical trial nurse navigator at The Leukemia and Lymphoma Society (LLS), who discusses ways to incorporate clinical trials in the shared decision-making process and LLS services that are available to support patients and providers.   “You do what the patient feels is best, you know, you look at what their values are and what's important to them, and then you try to find a therapy that fits those.” – Christopher Nelson, ACNP   “I think it's really important to try and make every patient aware of the fact that a clinical trial could be right for them at any stage in the game.” – Meghan McGrath, MSN, RN, AGACNP   Christopher Nelson, ACNP  Oncology Nurse Practitioner   Avera Medical Group Oncology & Hematology  Aberdeen, SD    Meghan McGrath, MSN, RN, AGACNP    Clinical Trial Nurse Navigator   The Leukemia and Lymphoma Society (LLS)      Resources:   ·      ACCC Treatment for Double-Exposed CLL - https://bit.ly/4iSmfV1 ·      ACCC CLL Resources - https://bit.ly/3E4QqZK ·      LLS Clinical Trial Support Center - https://bit.ly/42sqGQk ·      ACCC CLL Video Series - https://bit.ly/4la4li5

It is an honor and a privilege to welcome back Ethan Zohn to The Jake's Take with Jacob Elyachar Podcast. Ethan became a household name when he first appeared on Survivor: Africa, the third season of the legendary US reality TV competition. He won seven challenges and the title of “Sole Survivor.” He appeared on Survivor: All-Stars, where he won four challenges but lasted only 21 days, and returned to compete in the milestone season Survivor: Winners at War, where he only won one challenge and lasted 35 days.Since Survivor, Ethan has become an influential social entrepreneur. With a portion of his Survivor: Africa winnings, he co-founded Grassroots Soccer (GRS). GRS is an adolescent health organization that harnesses the power of soccer to provide young people with essential information, services, and mentorship they need to lead healthier lives. Since its inception, GRS has expanded to 60 countries in Africa and worldwide, has graduated 13 million youth, and has worked with scores of public—and private-sector partners.He also raised his voice to fight cancer.  Cancer-free since 2012, Ethan Zohn has been a voice for fighters, survivors, and caregivers of all ages, even chronicling the gritty details of his entire cancer experience for People Magazine. While undergoing treatment, he ran and finished the New York City and Boston marathons to help spread messages of hope and resilience to the world. Ethan is a champion for investment in new medical research and technology. He is an advisor to numerous hospitals and foundations, such as Cancer Buddy, the Leukemia and Lymphoma Society, and Memorial Sloan Kettering. As demonstrated by his charitable work, tzedakah, and community involvement, Ethan believes that Jewish values can achieve a better and healthier world. His inspiration to help heal the world stems from being taught at an early age the importance of community, a connection to the Jewish faith, and the preservation of Israel.  Ethan shares his deep bond to Judaism, his connection to the Jewish community, and his relationship with Israel by partnering with Jewish organizations that do critical work worldwide, such as BBYO, the Jewish National Fund, and Maccabi USA.On this episode of The Jake's Take with Jacob Elyachar Podcast, Ethan Zohn discussed Survivor's impact on Reality TV, creating the Crunch Bowl, combating antisemitism, and previewing Grassroots Soccer's Changemaker Cup.Become a supporter of this podcast: https://www.spreaker.com/podcast/jake-s-take-with-jacob-elyachar--4112003/support.

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.Featured Articles:Aging platelets shift their hemostatic properties to inflammatory functionsOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

This week on “Talk About Las Vegas With Ira,” Ira sits down with Steve Connolly, the powerhouse behind “Spirit of the King,” the ultimate Elvis tribute show at Notoriety Live every Wednesday, Thursday, and Sunday at 7 p.m. In this engaging conversation, Steve shares his eclectic journey—from playing bass guitar in high school and attending art school to restoring 700 statues and 123 churches. Initially set on becoming a curator, his path took an unexpected turn when a professor encouraged him to embrace both art and music. Steve talks about sneaking into bars with a fake I.D. at just 15 to play music, learning guitar, taking voice lessons, and how an open mic night changed his life forever—setting him on the road to embodying Elvis. He recalls the thrill of stepping in front of an audience, shedding inhibitions, and truly thriving in the spotlight. He recounts how “Legends in Concert” producer John Stuart and Will Collins helped bring him to Vegas, cementing his place as a dedicated student of Elvis. And how a critical letter pushed him to dive deeper into researching the King of Rock ‘n' Roll, refining his performance to a new level of authenticity. The key moment for Steve: before a particularly challenging performance (in front of a goth crowd), he asked for the spirit of Elvis to enter him—a ritual that has since become a pre-show prayer. Beyond the stage, Steve talks about his deeply personal commitment to the Leukemia & Lymphoma Society and how his family tragedy formed that commitment. Tune in for an episode filled with passion, music, and the magic of Vegas entertainment! (Also Watch Full Podcast Video)

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-negative blood group phenotype. The discovery that Mal protein is expressed on red blood cell membranes of AnWj-positive, but not AnWj-negative individuals, and that homozygous deletion in MAL causes the AnWj-negative blood group phenotype, helps answer a decades-old mystery related to the high prevalence red blood cell antigen AnWj and forms the basis of a new blood group system. 

Denna Arias from Energy Domain, Cory Mcintire from Wilbanks Reserve Corporation, and Greg Cohen from the Leukemia and Lymphoma Society (LLS) join the Philanthropy Series to discuss their personal journey's battling blood cancer, the advancements that have been made over the years, and what LLS is doing to raise awareness in order to help fund ongoing research that will ultimately end blood cancer once and for all. A big thanks to our 4 Minerals & Royalties Podcast Sponsors:--Tracts: If you are interested in learning more about Tracts title related services and software, then please call 281-892-2096 or visit https://tracts.co/ to learn more.--Riverbend Energy Group: If you are interested in discussing the sale of your Minerals and/or NonOp interests w/ Riverbend, then please visit www.riverbendenergygroup.com for more information--Farmers National Company: For more information on Farmer's land management services, please visit www.fncenergy.com or email energy@farmersnational.com--Oseberg: For more information on the software & data analytics tools that Oseberg has to offer, please visit www.oseberg.io.

In this week's episode, we'll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles:Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationHow I diagnose and treat acute infection–associated purpura fulminansSickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

BUFFALO, NY - March 31, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 21, 2025, titled “FGR Src family kinase causes signaling and phenotypic shift mimicking retinoic acid-induced differentiation of leukemic cells." A research team led by first author Noor Kazim and corresponding author Andrew Yen from Cornell University discovered that the FGR protein—traditionally considered a cancer-promoting molecule—can instead trigger leukemia cells to mature. This effect mirrors the response usually induced by retinoic acid (RA); a compound derived from vitamin A that is widely used in cancer therapy. Their finding presents a potential new path for therapies targeting acute myeloid leukemia (AML) and related cancers. Acute myeloid leukemia is often treated using RA-based therapies that force immature white blood cells to mature, slowing their rapid growth. Retinoic acid works through complex signaling and gene regulation involving a group of proteins that orchestrate this transformation. In this study, the team used HL-60 cells, a model for human leukemia, and engineered them to express FGR. Surprisingly, the presence of FGR alone was enough to make these cells mature in a way almost identical to what happens with RA treatment. They began producing well-known markers of maturation such as CD38 and CD11b, generated reactive oxygen species (ROS), and expressed the inhibitor of the cell cycle, p27, all signs that the cells had shifted from a cancer-like, fast-dividing state to a more specialized, mature form. Further analysis revealed that FGR activated a group of proteins known as the "signalsome," which helps trigger the changes needed for cells to differentiate. This same group is typically activated by RA. “Notably, FGR induces the expression of genes targeted by RAR/RXR, such as cd38 and blr1, even without RA." To test its potential use in treatment-resistant leukemias, the researchers introduced FGR into RA-resistant HL-60 cells. In these, FGR did not cause the same maturation process, which suggests that there are other problems with cell signaling that stop both the RA and FGR pathways. This result highlights the complexity of resistance mechanisms and the need for additional research. These findings challenge the traditional view of FGR as strictly a cancer-driving protein. Instead, in this specific context, it appears to initiate anti-cancer behavior. That a single protein can reproduce the effects of a complex therapeutic compound like RA is both surprising and promising. If future research confirms this study's results in more advanced models, FGR could become a new tool for developing therapies for AML and potentially other blood cancers. DOI - https://doi.org/10.18632/oncotarget.28705 Correspondence to - Andrew Yen - ay13@cornell.edu Video short - https://www.youtube.com/watch?v=v2fjeFFoUPQ Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The boys are joined by Jonathan Daige, a current cop and SWAT operator and survivor of testicular cancer, lung cancer, and brain cancer. He now suffers from Leukemia. Through all of this, JD still tackles life harder than most. Please consider joining our Patreon! https://patreon.com/TheAntiheroPodcast?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLink Check out our sponsors!! Human Performance Team (promo code "HERO" for 10% off!) https://hptrt.com/ Ghost Bed (promo code "Ghostbed" for 50% off!) https://www.ghostbed.com/pages/antiheroutm_source=podcast&utm_campaign=antihero Cloud Defensive (promo code "ANTIHERO15" for 15% off!) https://clouddefensive.com Zero 9 Holsters (promo code "ZERO9ANTIHERO10" for 10% off!) https://zero9holsters.com/ Venjenz (promo code "ANTIHERO" for 15% off!) https://venjenz.com/ Refracted Wolf Apparel (promo code "ANTIHERO" for 15% off!) https://refractedwolfapparel.com/ First Responders Coffee Company (promo code "FRCC15" for 15% off!) https://frccoffee.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     BPC-157  The 5 Tibetans (book review) Combination Therapy for Leukemia (AML) (research) Fluoride in Water (research)     For all the details tune in to today's Cabral Concept 3332 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3332 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In today's episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

Join Nick Lamagna on a special BONUS episode of The A Game Podcast with our guests Jackson and Shaun Amiruddin, a father and son telling an inspiring story of how Jackson survived acute lymphoblastic leukemia at a very early age.  He is now getting the word out with a special fundraiser to bring a cure and awareness for this cause to stop families and children from suffering through Hope Chasers as he is looking for all of us to help.   There is a current campaign running for the Student Visionary of the year where Jackson is looking for donations.  We are proud to help promote a part of the Leukemia & Lymphoma Society's (LLS) Student Visionaries of the Year Campaign, working to raise as much as possible for LLS's mission as a global leader in the fight against blood cancer, LLS:  Help will go toward: Funds cutting-edge research leading to breakthroughs in immunotherapy, genomics and personalized medicine that are improving and saving the lives of patients Provides free education and support for blood cancer patients and families, including personalized, one-on-one support, assistance with identifying and enrolling in clinical trials, and more. Mobilizes thousands of advocates to drive policy changes that accelerate the development of new cancer treatments and break down barriers to care. Please consider joining this fight by making a donation. All donations are greatly appreciated and tax-deductible. Please visit my website often and tell friends who would also like to donate! Topics for this episode include: ✅ Amazing story of how a child beat Leukemia  ✅ Words of encouragement from a child to other kids suffering from illness today ✅ Advice for parents struggling with the stress and emotions of dealing with this situation ✅ Tips on how to pick the best doctor when emotions are on the line. ✅  How we can help save lives  + More See the show notes to connect with all things Hope Chasers! Connect with Hope Chasers: Hope Chasers Facebook Hope Chasers Instagram Student Visionary of The Year Fundraiser Follow Jackson Amiruddin on Instagram --- Connect with Nick Lamagna www.nicknicknick.com Text Nick (516)540-5733 Connect on ALL Social Media and Podcast Platforms Here FREE Checklist on how to bring more value to your buyers

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/FLAG-GO vs FLAG-IDA https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine CPX-351: Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.htmlAbstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.htmlMenin Inhibitors Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.htmlAbstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.htmlAbstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.htmlAbstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html FLT3 inhibitors Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html MDS Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html ATRA in MDS:  https://ash.confex.com/ash/2024/webprogram/Paper200433.html  

Today I have the immense privilege of speaking with Bangarra Dance Theatre's James Boyd. James is a proud Aboriginal man with connections to the Kunja and Muruwari people of southwest Queensland. Born on Wiradjuri country in Orange, as a little boy, James wasn't quick to use his words, and had delayed speech. James's mum and dad then began to notice other things—James kept getting bruises. At just five years of age, James was diagnosed with Leukemia. In this most incredible episode, James shares his journey through cancer, the lows of hospital life, and also the highs when James was introduced to movement and music therapy as part of his recovery. And with that, he was introduced to dance. James then shares how he successfully auditioned for the Hunter School of the Performing Arts, and then how his world opened up at NAISDA Dance College. James then shares how, with his Leukemia is in remission, what it was like to receive a call from Frances Rings, the artistic director of Bangarra Dance Theatre. And then his decision to move to Sydney, which not only changed the course of his love life, but also defined his career.James continues to dance with Bangarra Dance Theatre, sharing the joy of dance across Australia and the world. For Bangarra performance times and tickets, head to bangarra.com.au and to follow all of James's adventures, you can find him on Instagram @jamesrossboyd. Talking Pointes is produced on the lands of the Gadigal People of the Eora Nation, to whom we pay our greatest respects. Production dream team ✨Hosted by @byclaudialawsonProduced by @fjordreviewAdditional Production @clinttopicSound & Editing @outputmediaStudios @brightsidesydney@sawtoothstudios

In this conversation, The FARM team shares a mix of personal anecdotes, health updates, and insights into nutrition and recovery strategies. The discussion covers various topics including recent health experiences, racing performance, community events, and notable research findings. The conversation also delves into specific cases related to TMJ treatment, emphasizing the importance of proper assessment and care in managing such conditions.Chapters00:00 Wound Care and Patient Stories02:55 Health Updates and Illness Experiences05:41 Nutrition and Recovery Strategies08:25 Racing and Athletic Achievements11:25 Upcoming Events and Community Engagement13:56 Running Performance and Trends16:45 Golf and Sports Industry Insights19:53 Research Highlights and Clinical Applications30:15 Exploring EMF and Health Concerns36:12 Protein Intake: Myths and Realities41:44 Case Study: Overcoming Low Back Pain46:24 Understanding Brachioradial Pruritus53:38 TMJ Dysfunction: Diagnosis and TreatmentDr. Beau Beard, DC, MS, CCSP is the co-founder and clinic director of ⁠The FARM: Functional Athletic Rehabilitation and Movement⁠, specializing in health, human performance, and rehabilitation. Inspired by his own recovery from a femur fracture, Dr. Beard has become an internationally recognized speaker and educator, sharing expertise on running performance, environmental health, and clinical reasoning. Creator of ⁠Rethinking Running Rehab (Rx3)⁠ and ⁠The Art of Assessment⁠ courses, he's worked with professional athletes, Olympic medalists, and military units. Author of ⁠The Age of Movement ⁠and a TEDx Birmingham speaker, Dr. Beard's mission is to empower individuals to be Better Than Before.BeauBeard.comInstagram: ⁠@drbeaubeard⁠⁠YouTube Channel⁠

Christine Anderson and I met because she created my favorite running fuel, Organic Pure Fuel. During this episode, sponsored by Anderson's Maple Syrup, Previnex, BITCHSTIX, and Cure Hydration (pinch me), we talk about:Her temperature limit for running outside How I found Christine's product, Pure FuelGrowing up on a “sugar bush” in rural Wisconsin Her family's syrup business, Anderson's Maple Syrup and how it's nearly 100 years oldHow she was an elementary school teacher for 25 years The El Fernando Siesta Running Club (an entirely made up club with Christine and two of her college friends)Running through McDonald's (not the drive thru)The device she would use to track her mileage in college How her best friend, Elyse, got her into marathons When that same friend, Elyse, ran the LA Marathon with active leukemia that had just come back after nearly five years Life after losing her friend, Elyse, and saying “yes” to adventures she'd been considering like traveling with a band for a year playing the pianoHer time in Tokyo, Japan and running for mental health Signing up for her first marathon with Team in Training for the Leukemia and Lymphoma Society at the Twin Cities MarathonWhy she stays until the last finisher for every marathon How her hope and dream before she dies is to run a marathon in all 50 statesRace stories from her 39 marathons: South Dakota, AlaskaJoining the family business, Anderson's Maple Syrup, and launching Organic Pure Fuel, maple syrup in a pouch for athletes How she wants to love trail running but she's a “chicken about falling” The best post race experience she's had at the Houston Marathon How her parents are still living at age 96 and 90 and her dad still likes to work This is a SandyBoy Productions Podcast. Sponsor Details:- Previnex - ALLY15 for 15% off your first order- Organic Pure Fuel - FUEL20 for 20% off on their website- BITCHSTIX -ALLYB for 20% off your order- Cure Hydration - ALLYB for 20% off your first order

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Up for the Fight: How to Advocate for Yourself as You Battle Cancer―from a Five-Time Survivor by Bill C. Potts Amazon.com Billcpotts.com The guide endorsed by MD Anderson Cancer Center and the Mayo Clinic, and used by Leukemia and Lymphoma Society and Multiple Myeloma Research Foundation patients. Imagine a road map for the entire cancer journey, for both patients and their loved ones. That's what this book is. Think What to Expect When You're Expecting, but for navigating the complexities of a cancer diagnosis, its treatment, and beyond. Up for the Fight empowers you to take control of your cancer journey with advice from five-time cancer survivor Bill C. Potts. Learn to be your own advocate, build the right care team, and prioritize your emotional and mental well-being. Discover practical tips for comfortable treatment days, side effect management, and understanding test results. Gain valuable insights on diet, exercise, and staying active while navigating the impacts of treatment and the disease on your immune system. Special sections offer guidance for supporting loved ones with cancer, facing mortality with peace, and realigning your priorities to truly live your life to the fullest. This book equips you with the knowledge and tools you need to fight this battle, all from the perspective of a tenacious cancer veteran.About the author Bill C. Potts is a motivational speaker, creative business leader, energetic community builder, and dedicated father and husband. A five-time cancer survivor, he pursues life with the utmost passion and drive. While his kids say he's “sometimes slightly embarrassing,” they also admit he's the “toughest man we have ever met.” He loves his job and wakes up each morning expecting an A+ day—because every day is an A+ day, no matter the circumstances. An IRONMAN triathlete and the co-founder of marketing agency Remedy 365, Bill lives in St. Petersburg, Florida, with his wife, Kim, and their dog Pippa.

Help Kam and his mother if you can HERE Or copy and paste the link: https://gofund.me/bc372a96  

Description: In this funny, refreshing, and irreverent conversation about parenting, Jen welcomes Caitlin Murray to the show to talk about her Big Time Adulting community space, the blog (and now podcast) that Caitlin started when her 5-year-old son was in cancer treatment for Leukemia, as a place to connect with other moms and parents craving funny, provocative, no-nonsense entertainment to distract themselves from the hamster wheel of life Like a big sister, Jen offers encouragement to guide Cailin through the years to come, with the two ultimately agreeing that early childhood is hard but middle school is the real shit show. They commiserate over:  Spirit Weeks, PTA obligations, and signing reading logs The idea of the 'Hardship Olympics' that creates unnecessary competition among women / moms Comparison parenting and why authenticity resonates more with their communities than curated perfection How community and humor that can be found in the everyday chaos of parenting *** Thought-provoking Quotes: I had begun writing as a therapeutic outlet to family and friends. It was really just for me to put out there how I was feeling on these long days at the hospital and the things that I saw going on around me – the emotion and the stress of it all. I felt like I was protecting myself by saying exactly how I was feeling about what we were going through rather than having anyone assume what I was feeling or thinking. – Caitlin Murray By the time I had been through hell and back for over three years of pediatric cancer with my son, I knew my worth as a mother. I don't give a f*ck about what anyone has to say about who I am. I know I am a good damn mom. – Caitlin Murray The things that you lay in bed at night and obsess over – things that you did poorly, when you lost your shit, you missed something or you messed up – it just falls right out of your kids' brains. It's not the bones; it's the soft tissue that sticks and makes it into their adult psyche. ‘I was deeply loved, I lived in a safe, secure home / family, my mom was into me, my mom thinks I'm funny, we laughed a lot in our home.' That's the stuff that lasts. Everything else turns into funny, comedic material. – Jen Hatmaker Resources Mentioned in This Episode: McSweeney's article - Did You Even Consider Every Possible Lived Experience Before Recklessly Posting Your Chili Recipe on Social Media? - https://www.mcsweeneys.net/articles/did-you-even-consider-every-possible-lived-experience-before-recklessly-posting-your-chili-recipe-on-social-media Anne Lamott - https://amzn.to/4h6cwcO David Sedaris - https://amzn.to/3E48Qtm Edith Eger - https://amzn.to/4hoXdM4 You'll Grow Out Of It by Jessi Klein - https://amzn.to/40oiSNm Guest's Links: Caitlin's website - https://bigtimeadulting.blog/ Caitlin's Big Time Adulting podcast - https://open.spotify.com/show/7nBEnM3JLnpSsyzxWyKZJJ?si=3b76f80afad345b7 Caitlin's Instagram - https://www.instagram.com/bigtimeadulting/ Caitlin's Twitter - https://x.com/Caitlin98714163 Caitlin's Facebook - https://www.facebook.com/OfficialBigTimeAdulting Caitlin's Soul Snacks Newsletter - https://bigtimeadulting.beehiiv.com/ Connect with Jen! Jen's website - https://jenhatmaker.com/ Jen's Instagram - https://instagram.com/jenhatmaker Jen's Twitter - https://twitter.com/jenHatmaker/ Jen's Facebook - https://facebook.com/jenhatmaker Jen's YouTube - https://www.youtube.com/user/JenHatmaker The For the Love Podcast is presented by Audacy. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices